O

n the surface, a pregnant woman and a person with cancer would seem to have little in common. But both may have DNA that isn’t the sequence they were born with floating around in their blood.

That DNA — from a fetus or a cancer — provides a potential target for new, non-invasive tests. Some researchers and companies are leveraging expertise in either circulating tumor DNA or non-invasive prenatal testing to develop tests in the other field.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.